Halozyme Therapeutics Inc (HALO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $11.00B
Last updated: Nov 17, 2026 at 4:37 PM ET
Halozyme Therapeutics Inc (HALO) Stock Chart
Halozyme Therapeutics (HALO) has a latest price of $95.97 on Nov 17, 2026, 28.4% below its 52-week high of $134.00. Its price rose 37.0% over the past 12 months. The month-end price rose 1,416.9% over the 10 years through Oct 2026, a compound annual rate of 31.2%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $130.91 in Oct 2026 and its lowest $8.63 in Oct 2016, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart HALO with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for HALO.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 10.8%, and over 6 months it rose 39.6%. The month-end price rose 286.5% over the 3 years through Oct 2026, a compound annual rate of 56.9%.
| Period | Change |
|---|---|
| 1 month | -21.7% |
| 3 months | -10.8% |
| 6 months | +39.6% |
| 12 months | +37.0% |
| 12 months, with dividends | +37.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +286.5% | +56.9% |
| 5 years | +243.9% | +28.0% |
| 10 years | +1,416.9% | +31.2% |
Price by Year
Its best calendar year was 2020, when the price rose 140.9%, and its weakest was 2023, when it fell 35.0%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $130.91 | +94.5% |
| 2025 | $67.30 | +40.8% |
| 2024 | $47.81 | +29.4% |
| 2023 | $36.96 | -35.0% |
| 2022 | $56.90 | +41.5% |
| 2021 | $40.21 | -5.9% |
| 2020 | $42.71 | +140.9% |
| 2019 | $17.73 | +21.2% |
| 2018 | $14.63 | -27.8% |
| 2017 | $20.26 | +105.1% |
Trading Range
The price is 15.8% below its 50-day average of $114.04 and 12.0% above its 200-day average of $85.66.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $95.97 | |
| 52-week high | $134.00 | -28.4% |
| 52-week low | $61.23 | +56.7% |
| 50-day average | $114.04 | -15.8% |
| 200-day average | $85.66 | +12.0% |
Price Risk
Over 3 years, its largest fall from a peak was 33.9%.
| Measure | Value |
|---|---|
| 1-year beta | 0.62 |
| Largest fall, 1 year | -26.8% |
| Largest fall, 3 years | -33.9% |
Valuation
Halozyme Therapeutics traded at 16.3x earnings at the end of 2025, against a 5-year median of 15.8x.
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About HALO
What is HALO's 1-year price change?
Halozyme Therapeutics's price rose 37.0% over the past 12 months. With dividends included, the 12-month total return was 37.0%.
What is HALO's 5-year price change?
Halozyme Therapeutics's month-end price rose 243.9% over the 5 years through Oct 2026, a compound annual rate of 28.0%. These figures leave out dividends.
What is HALO's 52-week high and low?
Halozyme Therapeutics's 52-week high is $134.00 and its 52-week low is $61.23. Its latest price of $95.97 on Nov 17, 2026 is 28.4% below the high.
What is HALO's beta?
Halozyme Therapeutics's 1-year beta against the S&P 500 is 0.62, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 26.8%.
Is the HALO chart free?
Yes. Advanced Charting for HALO is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
HALO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors